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Metabolic dysfunction of adipose tissue due to oxidative
stress is considered the cause of several complications of
obesity, such as diabetes and cardiovascular disease (1–3).
Dysfunctional adipocytes are associated with the development of insulin resistance, hyperglycemia, atherogenic
dyslipidemia, and arterial hypertension, and they favor a
prothrombotic and proinflammatory state (4, 5). Oxidative stress in adipose tissue regulates adipogenic response
with adipocyte hypertrophy (6, 7). Adipocyte dysfunction
is caused by a variety of stimuli, including heavy metals,
reactive oxygen species (ROS), nitric oxide (NO), Ang II,
and cytokines. The localized inflammation with increased
macrophage infiltration in adipose tissue leads to important changes in adipocyte gene expression, with downstream effects on adipocyte lipid metabolism and altered
endocrine function (7). Adipocyte differentiation (adipogenesis) is a complex process that includes coordinated
changes in hormone sensitivity and gene expression in response to various stimuli, including lipid mediators (8).
20-Hydroxyeicosatetraenoic acid (20-HETE), a product
of the cytochrome P450 (CYP)-catalyzed -hydroxylation
of arachidonic acid, is a primary eicosanoid in the microcirculation that plays a role in the regulation of vascular
tone and renal tubular homeostasis (9–12). Perturbations
in the levels of 20-HETE in tissues and biological fluids
have been observed in multiple pathological states, including hypertension, kidney disease, and metabolic syndrome
(13–17). 20-HETE stimulates production of superoxide
and inflammatory cytokines, inhibits endothelial nitric oxide synthase (eNOS), and increases oxidative stress (18–20),
suggesting a possible role for 20-HETE in the regulation of
adipogenesis (21).

Abbreviations: BMI, body mass index; COX, cyclooxygenase; CYP,
cytochrome P450; 20-HETE, 20-hydroxy-5,8,11,14-eicosatetraenoic acid;
MSC, mesenchymal stem cell; PG, prostaglandin; PPAR, peroxisome
proliferator-activated receptor.
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Abstract 20-Hydroxy-5,8,11,14-eicosatetraenoic acid (20HETE), a product of the cytochrome P450 (CYP)-catalyzed
-hydroxylation of arachidonic acid, induces oxidative
stress and, in clinical studies, is associated with increased
body mass index (BMI) and the metabolic syndrome. This
study was designed to examine the effects of exogenous 20HETE on mesenchymal stem cell (MSC)-derived adipocytes.
The expression levels of CYP4A11 and CYP4F2 (major 20HETE synthases in humans) in MSCs decreased during adipocyte differentiation; however, exogenous administration
of 20-HETE (0.1–1 M) increased adipogenesis in a dosedependent manner in these cells (P < 0.05). The inability of
a 20-HETE analog to reproduce these effects suggested the
involvement of a metabolic product of 20-HETE in mediating its pro-adipogenic effects. A cyclooxygenase (COX)-1
selective inhibitor enhanced, whereas a COX-2 selective or a
dual COX-1/2 inhibitor attenuated adipogenesis induced by
20-HETE. The COX-derived metabolite of 20-HETE, 20OH-PGE2, enhanced adipogenesis and lipid accumulation
in MSCs. The pro-adipogenic effects of 20-HETE and 20OH-PGE2 resulted in the increased expression of the adipogenic regulators PPAR␥ and ␤-catenin in MSC-derived
adipocytes. Taken together we show for the first time that
20-HETE-derived COX-2-dependent 20-OH-PGE2 enhances
mature inflamed adipocyte hypertrophy in MSC undergoing
adipogenic differentiation.— Kim, D. H., N. Puri, K. Sodhi,
J. R. Falck, N. G. Abraham, J. Shapiro, and M. L. Schwartzman.
Cyclooxygenase-2 dependent metabolism of 20-HETE increases adiposity and adipocyte enlargement in mesenchymal stem cell-derived adipocytes. J. Lipid Res. 2013. 54:
786–793.

MATERIALS AND METHODS
Human bone marrow-derived MSC differentiation
into adipocytes
Frozen bone marrow mononuclear cells were purchased from
Allcells (Emeryville, CA). After thawing, mononuclear cells were
resuspended in an ␣-minimal essential medium (␣-MEM, Invitrogen, Carlsbad, CA) supplemented with 10% heat inactivated
fetal bovine serum (FBS, Invitrogen) and 1% antibiotics and
antimycotic (Invitrogen). The cells were plated at a density of
1–5 × 106 cells per 100 cm2 dish. The cultures were maintained
at 37°C in a 5% CO2 incubator. The medium was changed after
48 h and every 3–4 days thereafter. When the MSCs were confluent, the cells were recovered by the addition of 0.25% trypsin/
EDTA (Invitrogen). MSCs (passage 2–3) were plated in either a
75 cm2 flask or a 24-well plate and cultured in ␣-MEM with 20%
FBS up to a density of 2.0 × 104 cells/cm2. The medium was replaced with adipogenic medium, and the cells were cultured for
an additional 14 days. The adipogenic media consisted of complete culture medium supplemented with DMEM-high glucose,
10% (v/v) FBS, 10 µg/ml insulin, 0.5 mM dexamethasone
(Sigma-Aldrich, St. Louis, MO), and 1% antibiotics and antimycotic
(Invitrogen) in the presence and absence of the COX-1 inhibitor (2-valeryloxybenzoic acid, Cayman, Ann Arbor, MI) and
the COX-2 inhibitor (3-(4-methylsulphonylphenyl)-4-phenyl-5trifluoromethylisoxazol, Cayman) with and without 20-HETE,
20-HETE agonist (20-5,14-HEDE), or 20-OH-PGE2. 20-HETE,
20-HETE agonist, or 20-OH-PGE2 were added three times a

week at concentrations of 0.1 and 1 M. Inhibitors of COX-1
and COX-2 were added three times a week at a dose of 100 and
5 M, respectively.

Oil Red O staining
At day 14 of adipogenesis, 0.21% Oil Red O in 100% isopropanol (Sigma-Aldrich, St. Louis, MO) was used. Briefly, adipocytes
were fixed in 10% formaldehyde, washed in Oil Red O for 10 min,
rinsed with 60% isopropanol (Sigma-Aldrich). Then the Oil Red
O was eluted by adding 100% isopropanol for 10 min, and OD
was measured at 490 nm for 0.5 s reading. MSC-derived adipocytes were measured by Oil Red O staining (OD = 490 nm) after
day 14. Each value of Oil Red O staining was normalized by the
cell number.

Adipocyte size
Lipid droplets were measured using an ImagePro Analyzer
(Media Cybernetics Corporation, Silver Springs, MD). The MSCderived adipocytes were treated with increasing concentration of
20-OH-PGE2 (1–1,000 nM) every alternate day for 14 days. To
quantify the number and size of the lipid droplets in these images, a proprietary algorithm (patent pending) was developed
that segments circular staining patterns. The algorithm was then
applied to images obtained from the lipid optical channel for
cells exposed to different doses of 20-OH-PGE2.

mRNA isolation and real-time PCR quantification
Total RNA was isolated using the RNeasy mini kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions. Firststrand cDNA was synthesized with Roche reverse transcription
reagents. Total RNA (0.5–1 g) was analyzed by real-time PCR.
The quantitative real-time polymerase chain reaction (qRT-PCR)
was performed with the TaqMan gene expression assay on an
Applied Biosystems 7500 fast real-time PCR system according to
the manufacturer’s recommended protocol (Applied Biosystems,
Foster City, CA). Each reaction was run in triplicate. The comparative threshold cycle (CT) method was used to calculate the
amplification fold as specified by the manufacturer.

Western blot analysis
Western blot analysis of adipocyte cell lysate was carried out as
described previously (6, 26). Briefly, cells were placed in a homogenization buffer, and homogenates were centrifuged at 27,000 g
for 10 min at 4°C. The supernatant was used for the measurement
of COX-1, COX-2, PPAR␥, Mest, and ␤-catenin protein levels
(27, 28). The levels were quantified by scanning densitometry using
an imaging densitometer, normalized to the levels of total protein.

PGE2 measurement
PGE2 levels were determined in the culture supernatant. Multiple assays were conducted for quantification of the proteins
(AssayGate Inc., Ijamsville, MD). All measurements were performed
in triplicate.

Statistical analyses
Statistical significance between experimental groups was
determined by the Fisher method of analysis of multiple comparisons (P < 0.05 was regarded as significant). For comparison
between treatment groups, the null hypothesis was tested by either a single-factor ANOVA for multiple groups or the unpaired
t-test for two groups. Data are presented as mean ± SEM. Differences between experimental groups were evaluated with ANOVA
with Bonferroni corrections. Statistical significance was regarded
as significant at P < 0.05.
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Prostaglandins (PG) are known to play a variety of roles
in adipocytes and precursor cells that utilize the arachidonate cyclooxygenase (COX) pathway to generate PGs at different stages of the life cycle of adipocytes (8). COX consists
of two isozymes, COX-1 and COX-2, and is the rate-limiting
enzyme that catalyzes the conversion of arachidonic acid
into PGs by specific PG synthases (22). COX-1 is constitutively expressed in most cells, including adipocytes, whereas
COX-2 is induced in response to various stimuli, such as
cytokines and oxidative stress (23). COX-2 expression is
transiently enhanced in the early phase of adipogenesis.
Prostaglandin E2 (PGE2) and prostaglandin F2a (PGF2␣)
are anti-adipogenic factors that suppress the differentiation
of adipocytes (23). Arachidonic acid metabolism during
adipogenesis is a process governed at multiple levels, suggesting a complex role for PGs during fat cell development
(24). The relative contribution of COX-1 and COX-2 to the
regulation of adipogenesis remains to be resolved.
20-HETE plays an important role in inducing oxidative
stress (21), and as such, we hypothesize that 20-HETE
affects adipogenesis. We examined adipogenesis in mesenchymal stem cells (MSC), multipotent stromal cells that can
be induced to differentiate into adipocytes (25). 20-HETE
is also a substrate for COX metabolites; hence, the goal
of the present study was to evaluate the contribution of
20-HETE and its COX-derived metabolites to the regulation of adipogenesis. The results of this study suggest that
COX-derived 20-HETE metabolites are a potential therapeutic target in the treatment of obesity and its associated
disease states: hypertension, the metabolic syndrome, and
diabetes.

RESULTS
CYP4--hydroxylase and COX expression
during adipogenesis
The expression levels of CYP4--hydroxylases were determined in MSC before and after completion of adipogenesis as shown in Fig. 1A, B. MSC expressed relatively
high mRNA levels of CYP4A11 and CYP4F2 (the major
20-HETE producing CYP4--hydroxylases in humans) (17)
before the start of adipogenic differentiation. In adipocytes derived from MSC, mRNA levels of these hydroxylases were nearly undetectable. To evaluate COX activity
in MSC exposed to adipogenic environment, PGE2 levels
were determined in conditioned media (Fig. 1C). COX-1
and COX-2 inhibitors decreased PGE2 levels compared
with levels in the conditioned media without indomethacin. Addition of indomethacin, which is a dual COX-1 and
COX-2 inhibitor, further decreased PGE2 levels (Fig. 1C).

Fig. 1. Levels of mRNA for (A) Cyp4F11 and (B) Cyp4F2 and (C)
levels of PGE2 in MSC before and after adipogenic differentiation
(adipocytes). Data are expressed as means ± SE. *P < 0.05 versus
#
+
MSC, P < 0.05 versus vehicle, P < 0.05 versus COX-1 or COX-2
inhibitor.

788

Journal of Lipid Research Volume 54, 2013

Effect of 20-hydroxy-PGE2 on adipogenesis and
adipocyte hypertrophy
Previous studies have shown that 20-HETE is metabolized by COX to 20-OH-endoperoxides and consequently
to 20-OH-PGE2 (29, 30). Therefore, we examined the
effects of 20-OH-PGE2 on adipogenesis in the presence
or absence of COX-1 and COX-2 inhibitors. 20-OHPGE2 stimulated (P < 0.05) adipogenesis 4-fold as measured by lipid accumulation (Fig. 5). Neither COX-1 nor
COX-2 inhibitor, alone or together, prevented 20-OH-PGE2mediated increase in adipogenesis, suggesting a COXindependent action of this metabolite (Fig. 5). The effect
of 20-OH-PGE2 was concentration dependent (Fig. 6A). It
significantly increased lipid accumulation at 50 nM and had
maximal effect at 500 nM. Moreover, addition of PGE2 blunted the adipogenic activity of 20-OH-PGE2; PGE2 (10 nM)
inhibited the adipogenic activity of 20-OH-PGE2 (500 nM)
by 40% as evidenced by a reduction in lipid accumulation
measured as absorbance of Oil Red O from 0.38 ± 0.02 to
0.23 ± 0.02 (P < 0.05). In addition, 20-OH-PGE2 stimulated adipocyte hypertrophy as measured by lipid droplet
size. As seen in Fig. 6B, lipid droplet size increased 2- and
3-fold in response to 100 and 1,000 nM of 20-OH-PGE2.
These results strongly suggest that the COX-2 metabolite
20-hydroxy-PGE2 plays a significant role in inducing adipogenesis and that its effect may be antagonized by
PGE2.
Effect of 20 HETE and 20-OH- PGE2 on
adipogenic markers
We examined the effects of 20-HETE and 20-OH-PGE2
on ␤-catenin, PPAR␥, and Mest expression as adipogenic
differentiation markers, in the presence and absence of
COX-1 and COX-2 inhibitors (Fig. 7). Densitometry analysis showed that the expression of PPAR␥ and Mest (Fig.
7A, B, respectively) was significantly increased in the presence of 20-OH-PGE2 when the cells were treated with
COX-1 or COX-2 inhibitor or both. In contrast, ␤-catenin
expression significantly decreased in the presence of 20OH-PGE2 when the cells were treated with COX-1 or COX-2
inhibitor or both (Fig. 7C). Similar data were obtained
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Effect of 20-HETE and COX inhibition on adipogenesis
The effect of 20-HETE on lipid accumulation in MSCderived adipocytes was examined in the presence and the
absence of either a COX-1 or COX-2 inhibitor. 20-HETE
enhanced lipid accumulation in cells exposed to a COX-1
inhibitor but not in cells exposed to COX-2 inhibitor (Fig. 2).
The absence of such an effect of 20-HETE in cells treated
with a COX-2 inhibitor alludes to the role of COX-2derived 20-HETE metabolic product in mediating these
enhanced lipogenic effects (Fig. 2). The direct effect of

20-HETE on lipid accumulation in MSCs derived adipocytes was further refuted by the inability of a 20-HETE agonist [sodium 2-((5Z,14Z)-20-hydroxyicosa-5,14-dienamido)
acetate, 20-HEDE] to mimic the effects of exogenous
20-HETE as shown in Fig. 3. Results show that in presence
of COX-1 and COX-2 inhibitors, the 20-HETE agonist
20-HEDE had no significant effect on adipogenesis, thus
further substantiating the notion that a COX-2-derived
metabolic product has an enhanced adipogenic effect.
Subsequently, addition of the microsomal PGE2 synthase
inhibitor CAY10526 abolished the adipogenic effect of
20-HETE in the presence of a COX-1 inhibitor (Fig. 4).
Arachidonic acid, which can also be metabolized consecutively by CYP and COX enzymes to a similar product, was
less potent than 20-HETE; it had no effect at 0.1 and 1 µM,
and at 10 µM, it increased lipid accumulation by 20% (data
not shown).

with 20-HETE, except that in the presence of a COX-2 inhibitor, the effect was blunted (data not shown).

DISCUSSION
In the present study, we demonstrated the stimulatory
effect of exogenous 20-HETE on lipid accumulation in
MSC-derived adipocytes. 20-HETE, a metabolic product
of -hydroxylases, is produced in physiologically relevant
amounts by various tissues and cells, including the vascular

Fig. 3. Effect of a 20-HETE agonist on adipogenesis in the presence and absence of COX-1 or COX-2 inhibitor. Adipogenesis was
measured as the relative absorbance of Oil Red O at day 14 after
inducing adipogenesis as described in Materials and Methods.
Mean ± SE.
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Fig. 2. Effect of 20-HETE on adipogenesis in the presence and
absence of indomethacin, COX-1 inhibitor (valeroyl salicylate),
and COX-2 inhibitor (CAY10404). Adipogenesis was measured as
the relative absorbance of Oil Red O at day 14 after inducing adipogenesis as described in Materials and Methods. Mean ± SE, *P <
0.05 versus vehicle.

wall and hemopoeitic cells (29–31). 20-HETE has been
shown to contribute to the regulation of vascular tone and
control of blood pressure. Interestingly, along with its potent vasoconstrictor capacity, 20-HETE has been shown to
mediate cellular proliferation (32, 33), angiogenesis (34,
35), oxidative stress (19), and inflammation (18), all of
which may contribute importantly to the process of adipogenesis. Metabolic imbalance, frequently accompanying
pathophysiological conditions traditionally associated with
enhanced 20-HETE synthesis, was the focus of this study.
The -Hydroxylase expression declined in hMSCs as they
differentiated into adipocytes, thus limiting their autocrine
exposure to endogenously generated 20-HETE. This may
be a consequence of in vitro cell culturing conditions. The
ability of adipose tissue to produce 20-HETE needs to be
further assessed. Nevertheless, this does not preclude nonadipocyte sources of this eicosanoid, including 20-HETE
from the vascular smooth muscle cells of the arteries vascularizing the adipose tissues (10, 11, 13, 14) as well as
20-HETE from circulating blood cells (36, 37). We showed
a dose-dependent adipogenic response to 20-HETE in hMSCs, which was characterized by increased adipocyte
hypertrophy and increased lipid accumulation. These
findings highlight a potential role for 20-HETE in promoting lipid accumulation, which in turn has been strongly
linked to adipocyte dysfunction and disruption of energy
balance.
The inability of a 20-HETE analog to reproduce the enhanced adipogenic effects of 20-HETE led us to examine
the hypothesis that a catabolic product of 20-HETE may
be responsible for mediating these effects. 20-HETE is a
known substrate for COX-2 with the resultant formation
of 20-OH-PGG2 (30). Human MSCs have an abundance
of microsomal PGE synthase (mPGES-1), the product of
which, PGE2, is an inhibitor of adipogenesis (38). Findings
in this study suggested that a COX-2-dependent 20-HETE
metabolite, most probably 20-OH-PGE2, appears to mediate the adipogenic effect of 20-HETE on hMSCs-derived
adipocytes. Blockade of the adipogenic effects of 20-HETE
by a selective inhibitor of COX-2 or a specific mPGES-1
inhibitor supports this theory. In addition, administration
of 20-OH-PGE2 had a similar effect on hMSCs to that observed during 20-HETE treatment. 20-OH-PGE2 could also
be synthesized by the sequential metabolism of arachidonic acid by COX and -hydroxylases; however, this
seems unlikely due to the nearly absent expression of hydroxylases in maturing adipocytes.
Our hypothesis that the metabolic product of 20-HETE,
most likely 20-OH-PGE2, is primarily a derivative of COX-2
stems from the observation that 20-HETE has no measurable effects on lipid accumulation on adipocytes undergoing COX-2 blockade, either alone or in combination with
COX-1 blockade. Absence of a stimulatory effect of 20-HETE
on hMSC-derived adipocytes in the absence of any COX
blockade indicates the reciprocal effects of arachidonic acidderived PGE2 and 20-HETE-derived 20-OH-PGE2. PGE2 inhibits adipogenesis, and for this reason, in vitro analysis of
adipogenesis is traditionally carried out in a setting of COX
blockade. We propose that the COX-2-derived metabolic

Fig. 4. Effect of 20-HETE on adipogenesis in the
presence and absence of COX-1 inhibitor, COX-2 inhibitor, and the PGE2 synthase inhibitor (CAY10526).
Adipogenesis was measured as the relative absorbance of Oil Red O at day 14 after inducing adipogenesis as described in Materials and Methods. Mean ±
#
SE, *P < 0.05 versus vehicle, P < 0.05 versus control.
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showed a significant correlation between 20-HETE levels
and BMI, as well as with oxidative stress and endothelial
dysfunction in hypertensive individuals (43–46). A recent
study in our laboratory examined associations between circulating 20-HETE levels and the function of endothelial
progenitor cells in diabetic and nondiabetic patients undergoing cardiac bypass surgery. This study found that levels
of 20-HETE are significantly elevated in diabetic patients
and that 20-HETE correlated with BMI in both diabetic

Fig. 5. Effect of 20-OH-PGE2 on adipogenesis in the presence and
absence of COX-1 inhibitor and/or COX-2 inhibitor. Adipogenesis
was measured as the relative absorbance of Oil Red O at day 14 after
inducing adipogenesis as described in Materials and Methods. Mean
#
± SE, *P < 0.05 versus vehicle, P < 0.05 versus control.
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product of 20-HETE counteracts the anti-adipogenic effects
of PGE2. The source of PGE2 appears to be predominantly
COX-1, as the basal level of adipogenesis is far greater in
the presence of a COX-1 inhibitor than in the presence of
a COX-2 inhibitor. The combination treatment of hMSCs
with COX-1 and COX-2 inhibitors does not lead to increased
adipogenesis compared with cells undergoing COX-1 blockade alone, further strengthening the notion that the inhibitory eicosanoid PGE2 is principally a catabolic product
of COX-1.
Our proposal of the occurrence of reciprocal effects of
PGE2 and 20-OH PGE2 on adipogenesis in hMSCs is
strengthened by the demonstrations of a rightward shift
of the dose-dependent adipogenic response in cells concurrently exposed to low concentrations of exogenous
PGE2. The adipogenic activity of 20-HETE and 20-OH-PGE2
was associated with a marked increase in the expression
of two major pro-adipogenic factors, PPAR␥ and Mest,
and a decrease in ␤-catenin, which is a key anti-adipogenic
regulator (39). 20-HETE and its metabolites were implicated as PPAR␥ activators (40, 41). In addition to increasing lipid accumulation, 20-HETE also enhanced hMSC
COX-2 expression, which could provide a microenvironment more conducive to the formation of 20-OH-PGE2. It
is possible that 20-HETE and/or 20-OH-PGE2 stimulate
transcription activation of the PPAR␥ receptor and
thereby set in motion a pro-adipogenic program that is
further evidenced by increasing the expression of Mest
and suppressing ␤-catenin. Additional studies are needed
to fully identify the precise mechanisms of action of this
eicosanoid.
20-HETE has been shown to increase in experimental
models of diabetes and obesity (42). The clinical relevance
of 20-HETE as a pro-adipogenic agent has been suggested
in several studies. A report by Laffer et al. (15) showed a correlation between levels of 20-HETE and circulating insulin
in essential hypertension with obesity. Croft and colleagues

and nondiabetic patients (47). Taken together, these
studies and the current findings suggest that 20-HETE
may play an important role in the regulation of adipose
tissue.
In conclusion, we characterize a pro-adipogenic role
of 20-HETE in adipocytes that appears to be mediated by
a COX-2-dependent catabolic product. Additional analysis
suggested that the mediator in question is 20-OH-PGE2.

20-OH-PGE2 could serve as an antagonist to the PGE2dependent anti-adipogenic effects and contribute toward
adipocyte hypertrophy and dysfunctional adipogenesis
frequently associated with pathophysiological conditions,
such as the metabolic syndrome. A selective COX-2 inhibitor could ablate these effects and could, in part, be
used therapeutically in the fight against these chronic
pathological conditions.

Fig. 7. Effect of 20-OH-PGE2 on adipogenic markers. Expression of (A) PPAR␥, (B) Mest, and (C) ␤catenin was determined by Western blot analysis in
MSC-derived adipocytes. Quantitative densitometry
evaluation of the proteins ratio was determined. Data
are expressed as means ± SE, *P < 0.05 versus corresponding conditions without 20-OH-PGE2.
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Fig. 6. (A) Concentration-dependent effect of 20-OH-PGE2 on adipogenesis. Mean ± SE, *P < 0.05 versus
1 nM concentration of 20-OH-PGE2. (B) Effect of 20-OH-PGE2 on adipocyte size. Mean ± SE, *P < 0.05, and
**P < 0.01 versus control.
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